Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hospitalized patients who are at high risk for readmission who are at least 18 years of age.~2. Specifically patients with (a) admission diagnosis of COPD AND (b) either a prior non-elective hospitalization (One in the past 12 months) OR active smoker who are ready for discharge AND (c) are also found to have sleep-disordered breathing (AHI ≥ 10 per hour; \>3% oxygen desaturation for hypopneas) by overnight portable respiratory study prior to hospital discharge.~3. Bedside spirometry revealing evidence for obstructive lung disease (post-bronchodilator; GOLD stage II or greater (FEV1 \<70% predicted post BD).~4. No previous home Positive Airway Pressure (PAP) or Non- Invasive Ventilation (NIV) use within the past year~Exclusion Criteria:~1. Central sleep apnea (Central apnea index \>5 per hour; and/or \>50% are central apneas \& hypopneas)~2. Clinically unstable, i.e., Acute Respiratory Failure, hypotensive shock, uncontrolled cardiac ischemia or arrhythmias, requiring life support ventilation or as otherwise determined by the investigator~3. Participants with Stage III \& IV Chronic Heart Failure as defined by the New York Heart Association (NYHA) Classification~4. Known or expected contraindications for the use of non-invasive ventilation per the assessment of the investigator.~5. Lack of medical insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AVAPS-AE Non-invasive ventilation therapy (Type: EXPERIMENTAL): Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
- Standard of Care Group (Type: NO_INTERVENTION): Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.

Based on this trial design, predict the completion outcome and termination type (if applicable).